GlaxoSmithKline Pharmaceuticals Limited is a renowned Indian pharmaceutical company that operates in the research, development, manufacturing, and marketing of a wide range of prescription medicines, vaccines, and consumer healthcare products. As a subsidiary of the global healthcare giant Glaxosmithkline, the company carries forward its legacy of innovation, quality, and commitment to improving global health. The company operates through various business segments, including Pharmaceuticals and Consumer Healthcare. The Pharmaceuticals segment focuses on the development, manufacture, and marketing of prescription drugs across multiple therapeutic areas such as respiratory, dermatology, oncology, cardiovascular, and infectious diseases.
- GlaxoSmithKline Pharmaceuticals Limited reported Total Income for Q4 FY23 of ₹815.11 Crore down from ₹828.39 Crore year on year, a decline of 1.6%.
- Total Expenses for Q4 FY23 of ₹635.54 Crore down from ₹650.04 Crore year on year, a decline of 2.2%.
- Consolidated Net Profit of ₹133.43 Crore, down 89% from ₹1219.05 Crore in the same quarter of the previous year.
- The Earnings per Share is ₹7.88, from ₹71.96 in the same quarter of the previous year.